Why Half of Men Stop Taking Sildenafil Within a Year

Sildenafil is one of the most effective medicines of the past thirty years, and for most men who take it, it does what it is supposed to do. So here is a strange fact: if you follow a large group of men from the day they collect that first prescription, around half of them will have stopped within twelve months. Most did not stop because it failed them. They stopped for reasons nobody thought to warn them about.

Half of Men Stop Within the First Year

The most comprehensive look at this pooled twenty-two observational studies covering almost 163,000 men, with an average age just under fifty-nine. It found a discontinuation rate averaging 4% per month, which compounds to nearly half of all users stopping inside a year. Two details are worth sitting with. Dropout was higher in younger men, not older ones. And it was higher in men who had more other health conditions alongside.

A Portuguese study took a closer look, interviewing 327 men who had been prescribed a PDE5 inhibitor — the family of medicines sildenafil belongs to. Just under half, 48.9%, had stopped taking it. More than half of those quit inside the first three months. Among the men who also had diabetes, 73% had stopped.

The number that reframes the whole picture comes from a Korean study of 485 men across thirty-four clinics. It deliberately looked only at men for whom the medicine had demonstrably worked — men who had successful intercourse using it. Even in that group, 23.9% had not taken it at all in the previous year.

So if you have stopped, or you are quietly thinking about it, you are in very ordinary company. That is worth knowing, because the assumption most men make is that they are the exception.

So Why Do Men Stop?

The reasons cluster into a handful of groups, and only some of them have anything to do with pharmacology.

The largest single category in the Portuguese study was the medicine not working well enough, at 36.8%. Lack of efficacy was also one of the two leading reasons across the whole meta-analysis. Hold that thought, because the next section complicates it considerably.

Psychological factors came next, at 17.5%. That covers anxiety, fear, low expectations and the beliefs a man brings to the bedroom with him. A further 8.7% stopped because they were worried about the cardiovascular safety of the medicine itself.

Then there is the spontaneity problem, and in the Korean study it was the single most common reason of all. Thirty-one percent simply did not want sex to depend on a tablet. Related answers in the same study included the psychological weight of planned, scheduled intercourse at 9.5%, and not feeling emotionally ready to restart sexual activity after a long gap at 12.9%. None of this is about whether the medicine works. It is about what sex means to a person, and what it costs them to feel they need help with it.

Cost mattered too. Just over a quarter of the Korean group, 26.7%, named the price of the medicine. That is a landscape which has shifted enormously since the original patents expired and generic sildenafil arrived.

Partner-related problems were one of the two leading causes in the meta-analysis, and in the Korean study 5.2% pointed specifically to a partner being unprepared after a long absence of sex.

Finally, and this deserves saying out loud: not every stop is a failure. Recovery of erectile function accounted for 14.4% of discontinuations in the Portuguese study, and in the Korean study 30.2% said their function had returned without needing further medication. Some men stop because they no longer need to carry on.

"It Didn't Work" Often Means "It Wasn't Used Properly"

This is the most useful finding in the entire literature, and it almost never reaches the people who need it.

A Greek study took 100 consecutive men who had been written off as sildenafil non-responders and asked them, in detail, how they had actually been using it. Inappropriate use was identified in fifty-six of them. Forty-five had never tried the highest recommended dose. Thirty-two had taken it on a full stomach straight after a meal. Twenty-two had taken it immediately before sexual activity rather than well in advance. And twelve did not know that sexual stimulation was still required for it to do anything at all.

Only thirty-four of the hundred said their doctor had arranged any follow-up appointment. After correct dose titration and timing instructions, thirty-one of these non-responders responded.

A separate rechallenge study found the same pattern. Of sixty men presenting as non-responders, forty-four had at least one major problem with how they were taking it. Thirty percent did not know arousal was necessary. Sixty percent had tried it fewer than four times before concluding it did not work. Forty-five percent had never taken the full 100mg dose. Given individual instruction based on how they had been using it, plus a scheduled follow-up, 58.5% went on to report successful intercourse.

This is not a claim that every man labelled a non-responder will respond with better instructions. Plenty will not. Some erectile difficulties have causes that a tablet cannot do much about, and identifying those properly matters. What the research does show is that "it didn't work" is a verdict a great many men reach before the medicine has had anything like a fair test.

The Conversation Most Men Never Have

One thread keeps reappearing across this research: the men who stay on treatment are the ones who are not doing it alone.

In the Portuguese study, men whose partners were involved in the treatment were significantly less likely to stop. Older men were also less likely to stop, which cuts against the intuition that this is a young man's advantage to lose.

And yet secrecy is closer to the norm. Research gathered in the meta-analysis found that fewer than 40% of men using a PDE5 inhibitor for mild or moderate difficulties had told their partner they were using it. The same body of work notes that women whose partners were successfully treated reported more satisfying sexual experiences than women whose partners were not.

None of which means a tablet repairs a relationship. It does not, and the evidence makes no such claim. What the research points to is narrower and far more practical. A man who tells his partner, and who goes back for a second appointment, is considerably more likely to still be getting something out of treatment a year later than a man who handles the whole thing quietly on his own.

The Science, in Brief

• Sildenafil citrate Sildenafil citrate belongs to a group of medicines called PDE5 inhibitors. When a man is sexually aroused, nerve signals release nitric oxide in the penis, which raises levels of a messenger molecule called cGMP, and cGMP relaxes the smooth muscle in the blood vessels so blood flow increases. An enzyme called PDE5 breaks that messenger down again. Sildenafil blocks the enzyme, so the signal lasts longer and the response is stronger. This is why it is not an aphrodisiac and does nothing on its own — arousal has to start the process; sildenafil only amplifies what is already happening. It is not suitable for everyone, and it must never be combined with nitrates. Discussed here as pharmacology and research, not as a product recommendation.

Sildenafil does not fail or succeed in a vacuum. Timing, food, dose, arousal, expectations, follow-up and partner communication all shape what happens next. The lesson from the research is not that every man should stay on it. It is that many men stop before anyone has helped them understand how to give it a fair, informed try.

This article is intended for informational and educational purposes only. It does not constitute medical advice and should not be used as a substitute for guidance from a qualified healthcare professional. Any medicine mentioned is discussed as science and research, not as a recommendation — never start, stop or combine any medication without speaking to a doctor or pharmacist, and never obtain prescription medicines from unregulated sources.